| Primary information |
|---|
| sequence ID | Seq_1200 |
| Peptide sequence | DEAGSEADHEGTHSTK |
| CancerPDF_ID | CancerPDF_ID1242, CancerPDF_ID3622, CancerPDF_ID9680, |
| PMID | 21136997,27026199,21533267 |
| Protein Name | Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Urine,Serum |
| M/Z | 1669.68159,NA,557.57 |
| Charge | 1,NA,3 |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,1669.68,NA |
| Profiling Technique | LC-MS,"CE-MS, Micro-TOF-MS",LC-MS |
| Peptide Identification technique | LC-MS-MS/MS,MS-MS,LC/MS/MS |
| Quantification Technique | LC-ESI-MS,NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID1242, CancerPDF_ID3622, CancerPDF_ID9680, |
| p-Value | NA,less than 0.05,NA |
| Software | MASCOT(v. 2.2.01),Proteome Discoverer 1.2,MASCOT |
| Length | 16,16,16 |
| Cancer Type | Colorectal cancer,Bladder cancer,Lung adenocarcinoma |
| Database | SwissProt Database,Uniprot Human non-redundant Database,Swissprot Database (57.4) |
| Modification | NA,NA,NA |
| Number of Patients | 30 patients and 30 healthy controls, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,Differentially expressed between recurrence of UBC vs recurrence control,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Leave One out Cross validation,Independent Validation,MRM-based validation of 19 candidates |
| Sensitivity | NA,For testing dataset 88%,NA |
| Specificity | NA,For testing dataset 51%,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |